Zhejiang Anglikang Pharmaceutical Co., Ltd.
Clinical trials sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical company producing generic drugs and active pharmaceutical ingredients.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Experimental drug put to the test against Hard-to-Treat GI cancers
Disease control Not yet recruitingResearchers are testing an experimental injectable drug called ALK-N001 in adults with advanced gastrointestinal tumors, including esophageal and colorectal cancers that have worsened after standard treatment. The phase II trial gives the drug intravenously every two weeks at one…
Phase 2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…
Phase 1/2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC